Tweet
C1q-targeted therapies for complement-related diseases are emerging as a promising approach to modulate the complement system. By specifically inhibiting or regulating C1q, a key initiator of the classical complement pathway, these therapies aim to address conditions like autoimmune disorders, neurodegenerative diseases, and inflammatory conditions. With their potential to reduce pathological immune responses, C1q-targeted therapies for complement-related diseases offer a novel avenue for developing effective and targeted treatments.